Feed/Companies/Microbiotica

Microbiotica

As of 16 Oct 2026, Microbiotica has raised $47.7M across 1 verified round on record (amounts in other currencies converted to USD), plus 2 rounds still being checked; latest: £36 million ($48 million) Series C led by British Business Bank, announced 16 Oct 2026.

BUILT ON

A clinical-stage biopharma company developing a pipeline of orally-dosed, precision microbiome medicines

microbiotica.comLinkedInCambridge, United KingdomBiotechFounded 2016

LATEST ROUND

Series C

$47.7M · 2026-10-16

RAISED ON RECORD · USD

$47.7M

across 1 verified round · plus 2 rounds still being checked

INVESTORS

3 leads

SOURCES

Feed/Companies

Company

Every round on record, with the sources behind each and the investors on them.

BUILT ON

Rounds

[ 3 ]

Series C

$47.7M · 2026-10-16

led by British Business Bank

Series B

$65.9M · 2022-03-07

[ HISTORY ]

led by Tencent, Flerie Invest

Funding round

$5.2M · 2018-10-24

[ HISTORY ]

lead not stated

Round	Amount	Announced	Lead	Buzz
Series C	$47.7M £36M ($48 million) incl. secondary £36 million ($48 million)	2026-10-16	British Business Bank	6 outlets. #44 in Trending
8 sources · checked 1 time, last 48m ago [ VERIFIED · CORRECTED ] read against 1 of 8 sources Amount added £36 million ($48 million) · markets.businessinsider.com The source states that all existing Series B investors participated but does not identify them in that sentence; only investors explicitly named as participating in this financing are listed.

Company research

Fetched today

Microbiotica is a clinical-stage biopharmaceutical company developing orally dosed precision microbiome medicines—defined live biotherapeutic products—for immuno-oncology and inflammatory bowel disease.

Founders

Trevor Lawley · co-founder and Chief Scientific Officer
Gordon Dougan · co-founder
At the time of the spin-out, Gordon Dougan was Professor and Head of Pathogen Genomics at the Wellcome Sanger Institute (and is described elsewhere as the former head of its Parasites and Microbes Programme).
Mike Romanos · co-founder and former CEO
Before founding Microbiotica, Mike Romanos held senior global roles at GSK and was CEO of Cambridge biotech Crescendo Biologics from 2011 to 2015.

Business model

Microbiotica develops its own oral microbiome medicines and monetizes partnered discovery and development through upfront payments, research, development and commercialisation milestones, royalties, and potential licenses of resulting assets.

Competitors

Seres Health, Vedanta

WHY IT MATTERS

Microbiotica is targeting major unmet needs in ulcerative colitis and cancer immunotherapy with oral, defined bacterial consortia selected through clinical-data-led microbiome profiling, including MB310 for ulcerative colitis and MB097 to improve response to immune checkpoint inhibitors in melanoma. On 16 October 2026 it announced the first close of a £36 million Series C led by British Business Bank to advance MB310 into Phase 2 after positive Phase 1b results, while the company’s own prior funding pages report £62M of equity financing to date.

Series B [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	$65.9M £50 million ($67 million)	2022-03-07	Tencent, Flerie Invest	No recent discussion
2 sources [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 of 2 sources Now a participant Tencent The Cambridge, UK dateline is not stated as the company's headquarters. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]2 pages read: microbiotica.com, onenucleus.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 of 2 sources·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent

Funding round [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	$5.2M £12m financing total £4m	2018-10-24	not stated	No recent discussion
1 source [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 source Date 2018-10-30 → 2018-10-24 · biospace.com Removed Cambridge Innovation Capital, IP Group · not in this round The article was published on October 30, but the company announcement's dateline fixes the announcement date as October 24. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: biospace.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 source·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent

Microbiotica

Company

Rounds

Sources

Profile

Investors

Microbiotica

Rounds

Company research

Sources

Series C$47.7M2026-10-168 sources

Series B$65.9M2022-03-072 sources

Funding round$5.2M2018-10-241 source

Investors

Series C$47.7M2026-10-166 investors

Series B$65.9M2022-03-076 investors

Funding round$5.2M2018-10-241 investor